Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 plus chemotherapy in CLDN18.2-positive advanced pancreatic cancer
NCT07079228Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QLS-31905 in pancreatic cancer (PC), sponsored by Qilu Pharmaceutical. Started Sep 2025; status: recruiting.
02
Drugs
QLS-31905
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07079228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079228.